C-reactive protein: A poor marker of cardiovascular disease risk in HIV+ populations with a high prevalence of elevated serum transaminases

Marianna K. Baum, C. Rafie, S. Sales, S. Lai, R. Duan, D. T. Jayaweera, J. B. Page, A. Campa

Research output: Contribution to journalArticle

3 Scopus citations


Blood lipids and high-sensitivity C-reactive protein (hsCRP) are used to assess cardiovascular disease (CVD) risk. We evaluated in a cross-sectional design the relationship of hsCRP to markers of liver function (aspartate and alanine transaminases [AST and ALT, respectively]), CVD risk factors and HIV-disease progression markers in 226 HIV-1 sero-positive drug users. hsCRP showed a significant inverse relationship with ALT and high-density lipoprotein, independent of age, gender, viral load, CD4 cellcount and antiretroviral (ARV) use, and was not significantly associated with HIV-disease progression markers. Serum markers of liver damage, AST and ALT, were associated with lower hsCRP, total cholesterol, low-density lipoproteins and triglycerides. Elevated liver enzymes (≥40 IU/L) were predictive of hsCRP levels that are considered a low risk for CVD. In conclusion, hsCRP may not be a reliable marker of CVD risk in populations with HIV at-risk for elevated liver enzymes due to high hepatitis B virus/hepatitis C virus prevalence and ARV use.

Original languageEnglish (US)
Pages (from-to)410-413
Number of pages4
JournalInternational Journal of STD and AIDS
Issue number6
StatePublished - Jun 1 2008



  • ALT
  • AST
  • C-reactive protein
  • CVD risk
  • HIV-1
  • Liver damage

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Immunology

Cite this